Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Free Report) CFO Sravan Kumar Emany bought 36,072 shares of the firm’s stock in a transaction on Friday, September 15th. The shares were purchased at an average price of $8.32 per share, for a total transaction of $300,119.04. Following the completion of the transaction, the chief financial officer now owns 188,730 shares of the company’s stock, valued at approximately $1,570,233.60. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Ironwood Pharmaceuticals Stock Performance
Shares of IRWD opened at $8.61 on Tuesday. The stock has a 50-day moving average price of $9.81 and a 200 day moving average price of $10.39. Ironwood Pharmaceuticals, Inc. has a one year low of $8.07 and a one year high of $12.66. The company has a market capitalization of $1.34 billion, a P/E ratio of -1.43 and a beta of 0.96.
Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.25 by $0.06. The business had revenue of $107.38 million for the quarter, compared to analysts’ expectations of $103.46 million. Ironwood Pharmaceuticals had a positive return on equity of 55.17% and a negative net margin of 214.68%. As a group, equities research analysts forecast that Ironwood Pharmaceuticals, Inc. will post 1.28 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Get Our Latest Report on Ironwood Pharmaceuticals
Institutional Trading of Ironwood Pharmaceuticals
Large investors have recently added to or reduced their stakes in the business. Natixis acquired a new stake in Ironwood Pharmaceuticals in the 4th quarter valued at approximately $30,000. Signaturefd LLC increased its position in Ironwood Pharmaceuticals by 778.9% in the 1st quarter. Signaturefd LLC now owns 3,173 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 2,812 shares during the period. Goodman Advisory Group LLC bought a new position in Ironwood Pharmaceuticals during the 1st quarter valued at $37,000. PNC Financial Services Group Inc. boosted its stake in Ironwood Pharmaceuticals by 41.4% during the 2nd quarter. PNC Financial Services Group Inc. now owns 3,647 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 1,067 shares in the last quarter. Finally, Lazard Asset Management LLC bought a new position in Ironwood Pharmaceuticals during the 1st quarter valued at $78,000.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries.
Featured Articles
- Five stocks we like better than Ironwood Pharmaceuticals
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- Stock Sentiment Analysis: How it Works
- 5 Reasons Mullen Automotive is About to Turn a Corner
- Financial Services Stocks Investing
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
